Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 628

1.

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.

Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI.

Clin Lymphoma Myeloma Leuk. 2019 Oct 9. pii: S2152-2650(19)32011-7. doi: 10.1016/j.clml.2019.09.624. [Epub ahead of print]

PMID:
31685378
2.

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV.

J Clin Oncol. 2019 Oct 25:JCO1901740. doi: 10.1200/JCO.19.01740. [Epub ahead of print]

PMID:
31652094
3.

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.

Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Oct 15. doi: 10.1002/ajh.25657. [Epub ahead of print]

PMID:
31612526
4.

Community-based Study of Celiac Disease Autoimmunity Progression in Adults.

Choung RS, Khaleghi S, Cartee AK, Marietta EV, Larson JJ, King KS, Savolainen O, Ross AB, Rajkumar SV, Camilleri MJ, Rubio-Tapia A, Murray JA.

Gastroenterology. 2019 Sep 24. pii: S0016-5085(19)41339-5. doi: 10.1053/j.gastro.2019.09.006. [Epub ahead of print]

PMID:
31560892
5.

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.

Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019 Sep 23:1-4. doi: 10.1080/13506129.2019.1666709. [Epub ahead of print]

PMID:
31544536
6.

MYC dysregulation in the progression of multiple myeloma.

Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortüm KM, Keats JJ; MMRF CoMMpass Network, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL.

Leukemia. 2019 Aug 22. doi: 10.1038/s41375-019-0543-4. [Epub ahead of print] No abstract available.

PMID:
31439946
7.

Surrogate endpoints in randomised controlled trials: a reality check.

Kumar S, Rajkumar SV.

Lancet. 2019 Jul 27;394(10195):281-283. doi: 10.1016/S0140-6736(19)31711-8. No abstract available.

PMID:
31354129
8.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486. No abstract available.

PMID:
31343331
9.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Br J Haematol. 2019 Jul 12. doi: 10.1111/bjh.16096. [Epub ahead of print]

PMID:
31298751
10.

Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.

Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J.

Cancer. 2019 Oct 15;125(20):3574-3581. doi: 10.1002/cncr.32357. Epub 2019 Jun 28.

PMID:
31251390
11.

Impact of acquired del(17p) in multiple myeloma.

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530.

12.

Multiple myeloma: Every year a new standard?

Rajkumar SV.

Hematol Oncol. 2019 Jun;37 Suppl 1:62-65. doi: 10.1002/hon.2586. Review.

PMID:
31187526
13.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
14.

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Leuk Lymphoma. 2019 May 16:1-8. doi: 10.1080/10428194.2019.1613536. [Epub ahead of print]

PMID:
31096812
15.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

16.

MAIA under the microscope - bringing trial design into focus.

Kapoor P, Rajkumar SV.

Nat Rev Clin Oncol. 2019 Jun;16(6):339-340. doi: 10.1038/s41571-019-0198-0. No abstract available.

PMID:
30850718
17.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

18.

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.

Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, Kumar SK.

Haematologica. 2019 Oct;104(10):2061-2074. doi: 10.3324/haematol.2018.211110. Epub 2019 Mar 7.

19.

Two types of amyloidosis presenting in a single patient: a case series.

Sidiqi MH, McPhail ED, Theis JD, Dasari S, Vrana JA, Drosou ME, Leung N, Hayman S, Rajkumar SV, Warsame R, Ansell SM, Gertz MA, Grogan M, Dispenzieri A.

Blood Cancer J. 2019 Mar 5;9(3):30. doi: 10.1038/s41408-019-0193-9.

20.

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, Leung N.

Br J Haematol. 2019 May;185(4):701-707. doi: 10.1111/bjh.15832. Epub 2019 Mar 5.

PMID:
30836444

Supplemental Content

Loading ...
Support Center